



## **LANSEN PHARMACEUTICAL HOLDINGS LIMITED**

**朗生醫藥控股有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 503)**

6 September 2011

Dear Shareholder(s),

### **Notification of publication of 2011 Interim Report (“Current Corporate Communication”)**

We hereby notify you that the Current Corporate Communication of Lansen Pharmaceutical Holdings Limited (the “**Company**”), in both English and Chinese, is now available on the Company’s website at [www.lansen.com.cn](http://www.lansen.com.cn) and HKExnews website at [www.hkexnews.hk](http://www.hkexnews.hk). You may access the Current Corporate Communication by clicking “Investor Relations” on the home page of the Company’s website or browsing through the HKExnews website.

Should you have any queries about how to obtain copies of the Current Corporate Communication or how to access the Current Corporate Communication on the Company’s website, please call the hotline of the Company’s Hong Kong share registrar, Tricor Investor Services Limited, at +852 2980 1333 during business hours (9:00 a.m. to 6:00 p.m., Monday to Friday, excluding public holidays) or send your written request to the Company’s Hong Kong share registrar at:

Tricor Investor Services Limited  
26/F, Tesbury Centre  
28 Queen's Road East, Wanchai, Hong Kong  
Email: [lansen-ecom@hk.tricorglobal.com](mailto:lansen-ecom@hk.tricorglobal.com)

The Company, upon your written request, will also send the printed version of the Current Corporate Communication to you free of charge. Furthermore, you are entitled, at any time, free of charge, by reasonable prior notice in writing either by post or by email to the Company’s Hong Kong share registrar, to change your choice of language or means of receipt of the Company’s future corporate communication(s).

Yours faithfully,  
For and on behalf of  
**Lansen Pharmaceutical Holdings Limited**  
**Stephen Burnau Hunt**  
*Chairman*